Investors & Media Company Overview UNITY Biotechnology is developing therapeutics to slow, halt or reverse diseases of aging. UNITY's initial focus is on creating medicines that target cellular senescence and aging-related biology in ophthalmologic and neurologic diseases, while leveraging partnerships in growth areas with high unmet need. Stock Information Data Provided by Refinitiv. Minimum 15 minutes delayed. Latest Presentation Download News Releases November 10, 2021 UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates November 9, 2021 UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease
November 10, 2021 UNITY Biotechnology, Inc. Reports Third Quarter 2021 Financial Results and Business Updates
November 9, 2021 UNITY Biotechnology Announces Improvement in Visual Acuity Sustained Through 24 Weeks Following Single Dose of UBX1325 in Phase 1 Study of Patients with Advanced Vascular Eye Disease
